

Timon Bogumil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6717598/publications.pdf>

Version: 2024-02-01

11

papers

597

citations

1040056

9

h-index

1281871

11

g-index

11

all docs

11

docs citations

11

times ranked

756

citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. <i>Journal of Neurology</i> , 2016, 263, 1418-1426.	3.6	42
2	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. <i>Journal of Neurology</i> , 2015, 262, 2466-2471.	3.6	4
3	Efficacy and safety of interferon beta-1b sc in older RRMS patientsâ€”a posthoc analysis of the BEYOND study. <i>Journal of Neurology</i> , 2013, 260, 1838-1845.	3.6	9
4	Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 1017.	9.0	37
5	Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. <i>Multiple Sclerosis Journal</i> , 2012, 18, 181-195.	3.0	33
6	Variability in detection and quantification of interferon Î²-1bâ€“induced neutralizing antibodies. <i>Journal of Neuroinflammation</i> , 2012, 9, 129.	7.2	9
7	250 $\frac{1}{4}$ g or 500 $\frac{1}{4}$ g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. <i>Lancet Neurology</i> , The, 2009, 8, 889-897.	10.2	377
8	Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 μ g QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel-group pilot study. <i>Clinical Therapeutics</i> , 2008, 30, 1102-1112.	2.5	15
9	Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. <i>Journal of Neurology</i> , 2004, 251, 1498-1501.	3.6	13
10	Interferon-Î²-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. <i>Journal of Neurology</i> , 2003, 250, 1224-1228.	3.6	46
11	Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients. <i>Neuroscience Letters</i> , 2002, 326, 125-128.	2.1	12